Does the media refer more to CNTB or IRD?

In the previous week, Connect Biopharma had 11 more articles in the media than Opus Genetics. MarketBeat recorded 14 mentions for Connect Biopharma and 3 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.11 beat Connect Biopharma's score of -0.14 indicating that Opus Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Opus Genetics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, AGMB or CNTB?

Connect Biopharma has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Connect Biopharma $60K 1,343.36 -$55.48M -$1.19 N/A

Is AGMB or CNTB more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Connect Biopharma N/A -165.41% -121.58%

Does the media prefer AGMB or CNTB?

In the previous week, Connect Biopharma had 6 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 14 mentions for Connect Biopharma and 8 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.48 beat Connect Biopharma's score of -0.14 indicating that AgomAb Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Connect Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CNTB or EIKN more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -165.41% -121.58% Eikon Therapeutics N/A N/A N/A

Does the media prefer CNTB or EIKN?

In the previous week, Connect Biopharma had 10 more articles in the media than Eikon Therapeutics. MarketBeat recorded 14 mentions for Connect Biopharma and 4 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.84 beat Connect Biopharma's score of -0.14 indicating that Eikon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CNTB or CABA more profitable?

Cabaletta Bio's return on equity of -128.27% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -165.41% -121.58% Cabaletta Bio N/A -128.27% -95.47%

Does the media favor CNTB or CABA?

In the previous week, Connect Biopharma had 12 more articles in the media than Cabaletta Bio. MarketBeat recorded 14 mentions for Connect Biopharma and 2 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.78 beat Connect Biopharma's score of -0.14 indicating that Cabaletta Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Cabaletta Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRTA or CNTB?

In the previous week, Connect Biopharma had 13 more articles in the media than Prothena. MarketBeat recorded 14 mentions for Connect Biopharma and 1 mentions for Prothena. Prothena's average media sentiment score of 1.02 beat Connect Biopharma's score of -0.14 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Connect Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral

Connect Biopharma (CNTB) Competitors

$1.28 -0.01 (-0.78%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.29 +0.01 (+0.78%)

As of 09/18/2026 07:55 PM Eastern

Compare

CNTB vs. IRD, AGMB, EIKN, CABA, and PRTA

Should you buy Connect Biopharma stock or one of its competitors? Connect Biopharma's main competitors and comparable companies include Opus Genetics (IRD), AgomAb Therapeutics (AGMB), Eikon Therapeutics (EIKN), Cabaletta Bio (CABA), and Prothena (PRTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Connect Biopharma compare to Opus Genetics?

Connect Biopharma (NASDAQ:CNTB) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Connect Biopharma currently has a consensus target price of $7.29, suggesting a potential upside of 469.20%. Opus Genetics has a consensus target price of $11.92, suggesting a potential upside of 130.18%. Given Connect Biopharma's higher probable upside, research analysts clearly believe Connect Biopharma is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

Opus Genetics has higher revenue and earnings than Connect Biopharma. Opus Genetics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	1,343.36	-$55.48M	-$1.19	N/A
Opus Genetics	$14.20M	30.15	-$49.59M	-$1.35	N/A

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by insiders. Comparatively, 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Connect Biopharma has a beta of -0.23, meaning that its stock price is 123% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

Connect Biopharma has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Connect Biopharma's return on equity of -165.41% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-165.41%	-121.58%
Opus Genetics	-1,091.82%	-338.88%	-150.13%

In the previous week, Connect Biopharma had 11 more articles in the media than Opus Genetics. MarketBeat recorded 14 mentions for Connect Biopharma and 3 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.11 beat Connect Biopharma's score of -0.14 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Opus Genetics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Connect Biopharma beats Opus Genetics on 10 of the 17 factors compared between the two stocks.

How does Connect Biopharma compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Connect Biopharma has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Connect Biopharma	$60K	1,343.36	-$55.48M	-$1.19	N/A

AgomAb Therapeutics' return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Connect Biopharma	N/A	-165.41%	-121.58%

In the previous week, Connect Biopharma had 6 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 14 mentions for Connect Biopharma and 8 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.48 beat Connect Biopharma's score of -0.14 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Connect Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.7% of Connect Biopharma shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

AgomAb Therapeutics presently has a consensus target price of $37.50, suggesting a potential upside of 208.13%. Connect Biopharma has a consensus target price of $7.29, suggesting a potential upside of 469.20%. Given Connect Biopharma's higher probable upside, analysts clearly believe Connect Biopharma is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Connect Biopharma beats AgomAb Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Connect Biopharma compare to Eikon Therapeutics?

Connect Biopharma (NASDAQ:CNTB) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

In the previous week, Connect Biopharma had 10 more articles in the media than Eikon Therapeutics. MarketBeat recorded 14 mentions for Connect Biopharma and 4 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.84 beat Connect Biopharma's score of -0.14 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eikon Therapeutics' return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-165.41%	-121.58%
Eikon Therapeutics	N/A	N/A	N/A

58.7% of Connect Biopharma shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Connect Biopharma has higher revenue and earnings than Eikon Therapeutics. Eikon Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	1,343.36	-$55.48M	-$1.19	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

Connect Biopharma currently has a consensus target price of $7.29, indicating a potential upside of 469.20%. Eikon Therapeutics has a consensus target price of $25.00, indicating a potential upside of 179.33%. Given Connect Biopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Connect Biopharma is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Connect Biopharma beats Eikon Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Connect Biopharma compare to Cabaletta Bio?

Connect Biopharma (NASDAQ:CNTB) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

58.7% of Connect Biopharma shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Connect Biopharma had 12 more articles in the media than Cabaletta Bio. MarketBeat recorded 14 mentions for Connect Biopharma and 2 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.78 beat Connect Biopharma's score of -0.14 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cabaletta Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cabaletta Bio's return on equity of -128.27% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-165.41%	-121.58%
Cabaletta Bio	N/A	-128.27%	-95.47%

Connect Biopharma currently has a consensus target price of $7.29, suggesting a potential upside of 469.20%. Cabaletta Bio has a consensus target price of $15.33, suggesting a potential upside of 501.31%. Given Cabaletta Bio's higher possible upside, analysts clearly believe Cabaletta Bio is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Connect Biopharma has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.27, meaning that its share price is 227% more volatile than the broader market.

Connect Biopharma has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	1,343.36	-$55.48M	-$1.19	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

Summary

Connect Biopharma beats Cabaletta Bio on 8 of the 14 factors compared between the two stocks.

How does Connect Biopharma compare to Prothena?

Prothena (NASDAQ:PRTA) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Prothena has a beta of -0.33, indicating that its stock price is 133% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market.

97.1% of Prothena shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 10.4% of Prothena shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Connect Biopharma had 13 more articles in the media than Prothena. MarketBeat recorded 14 mentions for Connect Biopharma and 1 mentions for Prothena. Prothena's average media sentiment score of 1.02 beat Connect Biopharma's score of -0.14 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prothena currently has a consensus price target of $24.57, indicating a potential upside of 186.38%. Connect Biopharma has a consensus price target of $7.29, indicating a potential upside of 469.20%. Given Connect Biopharma's higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Connect Biopharma has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Connect Biopharma	N/A	-165.41%	-121.58%

Connect Biopharma has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$54.53M	8.24	-$244.09M	-$0.84	N/A
Connect Biopharma	$60K	1,343.36	-$55.48M	-$1.19	N/A

Summary

Connect Biopharma beats Prothena on 9 of the 16 factors compared between the two stocks.

Get Connect Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTB vs. The Competition

Export

Metric	Connect Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$81.24M	$3.91B	$7.25B	$13.13B
Dividend Yield	N/A	3.64%	2.56%	12.94%
P/E Ratio	-1.08	14.08	273.81	25.39
Price / Sales	1,343.36	1,407.79	692.79	109.05
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	1.71	15.45	10.45	6.33
Net Income	-$55.48M	-$22.78M	$3.48B	$358.24M
7 Day Performance	-37.25%	-1.22%	0.88%	1.17%
1 Month Performance	-47.97%	-4.44%	-1.59%	-2.59%
1 Year Performance	-18.47%	37.78%	18.08%	5.97%

Connect Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTB Connect Biopharma	3.2305 of 5 stars	$1.28 -0.8%	$7.29 +469.2%	-20.5%	$81.24M	$60K	N/A	64	News Coverage Analyst Forecast Gap Down
IRD Opus Genetics	3.389 of 5 stars	$5.98 -1.5%	$11.92 +99.5%	+247.7%	$497.13M	$9.86M	N/A	14	High Trading Volume
AGMB AgomAb Therapeutics	3.6381 of 5 stars	$13.37 -4.1%	$37.50 +180.5%	N/A	$484.53M	N/A	N/A	62	Analyst Forecast
EIKN Eikon Therapeutics	2.08 of 5 stars	$8.87 -3.7%	$25.00 +182.0%	N/A	$480.81M	N/A	N/A	384	Positive News Analyst Upgrade
CABA Cabaletta Bio	3.0721 of 5 stars	$2.77 +0.9%	$15.33 +454.6%	+17.0%	$468.95M	N/A	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTB) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Connect Biopharma (CNTB) Competitors

CNTB vs. IRD, AGMB, EIKN, CABA, and PRTA

How does Connect Biopharma compare to Opus Genetics?

Summary

How does Connect Biopharma compare to AgomAb Therapeutics?

Summary

How does Connect Biopharma compare to Eikon Therapeutics?

Summary

How does Connect Biopharma compare to Cabaletta Bio?

Summary

How does Connect Biopharma compare to Prothena?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Connect Biopharma (CNTB) Competitors

CNTB vs. IRD, AGMB, EIKN, CABA, and PRTA

How does Connect Biopharma compare to Opus Genetics?

Do analysts rate CNTB or IRD?

Which has preferable earnings & valuation, CNTB or IRD?

Do insiders and institutionals hold more shares of CNTB or IRD?

Which has more volatility and risk, CNTB or IRD?

Is CNTB or IRD more profitable?

Does the media refer more to CNTB or IRD?

Summary

How does Connect Biopharma compare to AgomAb Therapeutics?

Which has higher earnings & valuation, AGMB or CNTB?

Is AGMB or CNTB more profitable?

Does the media prefer AGMB or CNTB?

Do institutionals and insiders hold more shares of AGMB or CNTB?

Do analysts prefer AGMB or CNTB?

Summary

How does Connect Biopharma compare to Eikon Therapeutics?

Does the media prefer CNTB or EIKN?

Is CNTB or EIKN more profitable?

Do institutionals & insiders believe in CNTB or EIKN?

Which has higher valuation and earnings, CNTB or EIKN?

Do analysts prefer CNTB or EIKN?

Summary

How does Connect Biopharma compare to Cabaletta Bio?

Do insiders and institutionals have more ownership in CNTB or CABA?

Does the media favor CNTB or CABA?

Is CNTB or CABA more profitable?

Do analysts rate CNTB or CABA?

Which has more risk & volatility, CNTB or CABA?

Which has higher earnings and valuation, CNTB or CABA?

Summary

How does Connect Biopharma compare to Prothena?

Which has more risk & volatility, PRTA or CNTB?

Do insiders & institutionals believe in PRTA or CNTB?

Does the media favor PRTA or CNTB?

Do analysts recommend PRTA or CNTB?

Is PRTA or CNTB more profitable?

Which has higher valuation & earnings, PRTA or CNTB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools